Adrenaline
Severe
Textbook
Marked rise in BP.
Adrenaline should not be given to patients receiving β blockers.
Source: KDT 7e · p133
Drug reference
Nadolol
Beta Blocker · Antiarrhythmic
Beta BlockerAntiarrhythmicATC C07AA06
CDSCO approvedSchedule HATC C07AA06
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Crosses the placenta but not known to be
FDA category + note
Top interactionssee all 12 →
- AdrenalineSevereTextbookKDT 7e · p133
- AmilorideSevereTextbookKDT 7e
- SofosbuvirSevereTextbookHarrison 22e · unknown
- AminophyllineSevereDatabaseDDInter
Mechanism
Nadolol is a non-selective beta-adrenergic receptor antagonist, blocking both "1 and "2 receptors. Beta-1 receptor blockade in the heart reduces heart rate and contractility. Beta-2 receptor blockade affects bronchial smooth muscle.
Indications
Arrhythmiashypertensionangina pectorismigraine prophylaxis (unlabeled)parkinsonian tremors (unlabeled)variceal bleeding in portal hypertension (unlabeled)performance anxietysituational anxietyArrhythmias in congenital long QT syndromeArrhythmias in catecholaminergic polymorphic ventricular tachycardia (CPVT)AnginaPrevention of arrhythmiasRate control in atrial fibrillationMigraine
Dosing
- Adult
- l INDICATIONS AND DOSE Cardiopulmonary resuscitation (as an alternative if amiodarone is not available) ▶ BY INTRAVENOUS INJECTION Adult: 1 mg/kg, do not exceed 3 mg/kg over the first hour Ventricular arrhythmias, especially after myocardial infarction in patients without gross circulatory impairment ▶ ▶ INITIALLY BY INTRAVENOUS INJECTION Adult: 100 mg, to be given as a bolus dose over a few minute…
- Renal adjustment
- dosage should be reduced in patients with renal failure
Pharmacokinetics
Half-life
about 20 h
Bioavailability
about 35% (oral), incompletely absorbed
Protein binding
lower concentrations in brain due to low lipid solubility
Metabolism
not extensively metabolized
Excretion
largely excreted intact in urine
Contraindications
- abrupt discontinuation (withdrawal syndrome)
- Asthma
- Peripheral vascular disease
- Hypoglycemia
- AV block (grade 2-3)
Side effects
Common
hypotensionBradycardiaBronchospasmPeripheral vasoconstrictionWorsening of acute heart failureDepressionWorsening of psoriasisIncreased triglyceridesDecreased HDL cholesterol
Serious
- Withdrawal syndrome (rebound hypertension, exacerbation of CAD symptoms)
- Severe hypertension and bradycardia (if used with epinephrine)
Pregnancy & lactation
Pregnancy
Crosses the placenta but not known to be
Drug interactions
Amiloride
Severe
Textbook
Hyperkalaemia more likely.
Source: KDT 7e
Sofosbuvir
Severe
Textbook
Severe bradycardia.
Extreme caution advised if amiodarone is co-administered with sofosbuvir and a beta blocker.
Source: Harrison 22e · unknown
Aminophylline
Severe
Database
Drug interaction classified as: antagonism
Source: DDInter
Arformoterol
Severe
Database
Drug interaction classified as: antagonism
Source: DDInter
Atazanavir
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Ceritinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Clonidine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Diltiazem
Severe
Database
Increased propensity for AV block, severe bradycardia, and decreased left ventricular function.
Avoid concurrent administration. The concurrent administration of diltiazem with a beta blocker is contraindicated.
Source: DDInter
Disopyramide
Severe
Database
Clinical effect not specified
Source: DDInter
Dolasetron
Severe
Database
Clinical effect not specified
Source: DDInter
Dyphylline
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Other Beta Blocker drugs
Ask House about Nadolol
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, BNF·Verified: 2026-05-13 · House clinical team